Perstorp Holding AB (Publ.)

Interim report 1 January – 30 September 2019



Interim report 1 January – 30 September 2019

Perstorp Holding AB (Publ.), corporate reg. no. 556667-4205, Parent company for Perstorp.

Perstorp is an international specialty chemicals Group and a global leader in high growth niches. The Group has around 1,350 employees and manufacturing facilities in Europe, North America and Asia. The Perstorp Group is controlled by the European private equity company PAI Partners.

Key figures in summary July - September 2019, continuing operations

- Net sales decreased with 5% to SEK 2,895 (3,037) m, reflecting mainly lower sales prices due to a combination of lower raw materials, weakening market conditions and increased competition.
- Organic volume-based sales growth was 2% year-on-year.
- EBITDA excluding non-recurring items amounted to SEK 439 (417) m.
- EBITDA-margin excluding non-recurring items was 15.2% (13.7).

SEK m unless otherwise stated	Quarter 3		Quarter 1-3		Latest	Full year
	2019	2018	2019	2018	12 months	2018
Net Sales	2,895	3,037	9,178	9,498	12,116	12,436
EBITDA	411	375	1,186	1,385	1,497	1,696
% of net sales	14.2	12.3	12.9	14.6	12.4	13.6
EBITDA excluding non-recurring items ¹⁾	439	417	1,279	1,438	1,655	1.814
% of net sales	15.2	13.7	13.9	15.1	13.7	14.6
Operating earnings (EBIT)	270	257	788	978	995	1,185
% of net sales	9.3	8.5	8.6	10.3	8.2	9.5
Net earnings/loss	-60	7	-1,172	-183	-944	45
Free cash flow	301	174	532	518	977	963

Key figures in summary, continuing operations

¹⁾ Non-recurring items are mainly attributable to restructuring and refinancing costs.



President's Comments – Q3 2019

"Even though we have to deal with weaker markets, it is important for us to maintain focus on our current performance, mitigating whatever we can, while remaining committed to where we are going longer term. We have great confidence in our growth potential and the strategic direction remains."

The third quarter was characterized by a continued slowdown in the world economy and in addition, the trade war between the US and China has resulted in excess volumes from competitors in China being moved to Southeast Asia and Europe. Correspondingly we have seen weaker demand in several of our product lines. The drop in raw material prices and to some extent increased competition pushed our price levels downwards, although we managed to keep up the margins in selective areas.

Lower average sales prices

All three regions, EMEA, APAC and Americas suffered from lower average sales prices. Demand continues to be weak in APAC and EMEA, whilst demand in Americas is holding up compared to third quarter last year, mainly driven by the Penta, Oxo and Formates businesses.

Net sales amounted to SEK 2,895 m, a 5% decrease over third quarter last year, mainly due to lower sales prices and partly offset by higher volumes and positive FX effects. Organic volume based sales growth for the period was 2% compared to the same period last year. EBITDA excluding non-recurring items amounted to SEK 439 (417) m with an EBITDA margin of 15.2% (13.7%), with cost controls measures, introduced in the second quarter this year, having giving positive contribution. LTM EBITDA was SEK 1,655 m compared to SEK 1,814 m for the full year 2018.

Mixed results from the Business Areas

In Business Area Specialty Polyols & Solutions, EBITDA amounted to SEK 296 (239) m. The improved result was driven by enhanced margins for some product lines, lower fixed cost and positive exchange rate effects. To some extent this was partly offset by softer demand and lower unit margins in APAC and EMEA.

For Business Area Advanced Chemicals, EBITDA amounted to SEK 138 (98) m were last year's result was negatively impacted by a scheduled maintenance turnaround. Unit margins has remained stable both within the alcohol and the plasticizer businesses, helped by lower raw material prices. The slightly weaker market conditions we started to see at the end of the second quarter continued in the third quarter, especially in APAC.

Business Area Animal Nutrition showed positive volume development, but margins were down. Gut health in Americas continued to show strong growth, APAC is however still hampered by African Swine Fever. Acid Solutions showed a temporary decline as a result of the product portfolio rationalization. There has also been a somewhat increased price pressure for some of the products due to new volumes coming into the market. EBITDA amounted to SEK 49 (58) m.

Continued cost control without losing our long term direction

Earlier initiated cost reduction initiatives started to show a positive contribution during the third quarter. Given the weaker market conditions we continue to further hold back on fixed costs and investments in the short term. We have our ears to the ground and are prepared to act with agility, both to capture new business opportunities but also to install further efficiency measures if demand would continue to decline.

Even though we have to deal with weaker markets, it is important for us to maintain focus on our current performance, mitigating whatever we can, while remaining committed to where we are going longer term. We have great confidence in our growth potential and the strategic direction remains. We are also confident that Business Area Animal Nutrition will deliver growth as set out in the plans. Most teams are now fully staffed and new contracts and customer relationships are on the way to being built up. We see early signs of this starting to bring results and I am personally convinced that we will be there in 2020.

It is extremely important to us that we have product available when it is needed from our customers. In order to further increase delivery security, but also to look at how we can find productivity improvements and capacity increases by working differently, we will gradually roll out a new Operational Excellence model to all our production sites. Our site in Perstorp is first out and has shown great commitment with results starting to appear. Activities to improve how we work with health and safety are also an important part for our long term success.

Safety performance on a positive trend

Our safety performance remains a top priority and is on a positive trend. The full year outlook indicates that we will be able to reach the target for process safety events, but not fully for OSHA (Occupational Safety and Health Administration) recordables. On October 23rd, we will hold our annual "Care 365 day" across the company for the second time, where the program will be all about health & safety related to the various locations.

As part of our focus on health and safety, we have now taken a decision to introduce "Care" as a fourth core value alongside "Responsibility", "Reliability" and "Focused Innovation". We strongly believe that a caring company long term is a more profitable company.

Malmö, October 2019

Jan Secher President and CEO

Financial overview July - September 2019

Income statement, continuing operations

SEK m	Quarter 3		
	2019	2018	
Net Sales	2,895	3,037	
Cost of goods sold	-2,427	-2,599	
Gross earnings	468	438	
Operating earnings (EBIT)	270	257	
Exchange rate effects on net debt	-140	107	
Other financial income and expenses	-163	-336	
Earnings before tax	-33	28	
Тах	-27	-21	
Net earnings/loss	-60	7	
EBITDA	411	375	
EBITDA excluding non-recurring items	439	417	

Net sales and earnings, continuing operations¹⁾

Net sales during the third quarter amounted to SEK 2,895 (3,037) m, a decrease of SEK 142 m or 5%.

Organic volume based sales growth was 2% in the third quarter 2019.

Excluding currency effects, sales prices were 8% lower than last year linked to lower raw material prices, weakening market conditions especially in APAC and EMEA and increased competition.

Average Dated Brent oil price decreased 18% in the third quarter 2019 compared to the corresponding quarter last year and was 8% lower than in the second quarter 2019. The lower price on Dated Brent oil, compared to the second quarter 2019, has also impacted pricing on downstream derivatives like propylene and ethylene during the third quarter of 2019.

The Swedish krona continued to weaken against both the USD and the EUR, resulting in positive exchange rate effects on sales of approximately 3% vs same quarter previous year.

EBITDA excluding non-recurring items amounted to SEK 439 m (417), corresponding to an EBITDA margin of 15.2% (13.7). The increase in EBITDA was attributable to higher volumes and improved unit margins for some product lines together with lower fixed costs and positive exchange rate impact partly offset by negative impact from weaker demand and increased price pressure. In the third quarter last year, EBITDA was negatively affected by approximately SEK 50 m linked to the maintenance turnaround in Stenungsund.

Depreciation and amortization amounted to SEK 141 (119) m including depreciation related to lease arrangement of SEK 9 (-) m. EBIT amounted to SEK 270 (257) m for the period.

Net financial expenses, excluding currency effects on net debt, amounted to SEK 163 (336) m, reflecting the refinancing of the capital structure, which was completed during the first quarter 2019.

Tax amounted to SEK -27 (-21) m and net result amounted to SEK -60 (7) m.

¹⁾ Continuing operations excludes the divested unites Perstorp UK Ltd, Perstorp Bioproducts AB and Perstorp Bioproducts AS.

Financial overview January - September 2019

Income statement, continuing operations

SEK m	Quarter 1-3		
	2019	2018	
Net Sales	9,178	9,498	
Cost of goods sold	-7,707	-7,941	
Gross earnings	1,471	1,557	
Operating earnings (EBIT)	788	978	
Exchange rate effects on net debt	-376	-445	
Other financial income and expenses	-1,502	-987	
Earnings before tax	-1,090	-454	
Тах	-82	271	
Net earnings/loss	-1,172	-183	
EBITDA	1,186	1,385	
EBITDA excluding non-recurring items	1,279	1,438	

Net sales and earnings, continuing operations¹⁾

Net sales for the first nine months of 2019 amounted to SEK 9,178 (9,498) m, a decrease of SEK 320 m or 3%. The sales decrease was resulting from softer demand mainly in APAC and EMEA and lower prices together.

Organic volume based sales growth was -2%. Excluding currency effects, sales prices in the first nine months of 2019 were 3% lower than last year due to both increased competition and lower raw material prices. During the first nine months of 2019, the Swedish krona weakened against the USD and EUR compared to the corresponding period in 2018, resulting in positive exchange rate effects on sales of approximately 5%.

EBITDA excluding non-recurring items amounted to SEK 1,279 (1,438) m, corresponding to an EBITDA margin of 13.9% (15.1). The decrease in earnings compared to last year of SEK 159 m was attributable to lower volumes and unit margins for some product lines and the unplanned shutdown in Stenungsund in beginning of the year which partly was offset by lower fixed cost and positive currency rate effects.

Non-recurring items, amounting to SEK 93 m, relates primarily to restructuring costs in connection with the reorganization. Depreciation and amortization for the period amounts to SEK 398 (407) m including depreciation related to lease arrangement of SEK 28 (-) m. The comparable numbers for 2018 includes an impairment of approximately SEK 57 m related to fixed assets in Perstorp Polialcoli S.r.l., Italy. EBIT amounted to SEK 788 (978) m for the period.

Net financial expenses, excluding currency effects on net debt, amounted to SEK 1,502 m compared to SEK 987 m for the same period in 2018. The deviation was mainly impacted by the refinancing of the capital structure, which was completed during the first quarter 2019. The refinancing lowered the average interest rate from approximately 8% to 5%, which had a full effect in the income statement from the second quarter 2019.

Tax amounted to SEK -82 (271) m. In 2018, deferred tax assets was assigned to tax losses carry forward due to the new tax rules in Sweden and positively affected the result with SEK 338 m. Net result amounted to SEK -1,172 (-183) m.

¹⁾ Continuing operations excludes the divested unites Perstorp UK Ltd, Perstorp Bioproducts AB and Perstorp Bioproducts AS.

Free cash flow analysis, continuing operations

SEK m	Quarter 3		Quarter 1-3		Latest	Full year
	2019	2018	2019	2018	12 months	2018
EBITDA excluding non-recurring items	439	417	1,279	1,438	1,655	1,814
Change in Working Capital ²⁾	30	-114	-366	-587	-90	-311
Maintenance Capex	-53	-103	-159	-233	-287	-361
Free Cash Flow before Strategic Capex	416	200	754	618	1,278	1,142
% of EBITDA excluding non-recurring items	95	48	59	43	77	63
Strategic Capex	-115	-26	-222	-100	-301	-179
Free Cash Flow	301	174	532	518	977	963
% of EBITDA excluding non-recurring items	69	42	42	36	59	53

¹⁾ For further details on total cash flow, please see page 17.

²⁾ Excluding currency translation effects and provisions.

Available funds and debt

SEK m	Sept 30, 2019	Sept 30, 2018	Dec 31, 2018
Available funds	942	1,119	1,120
Net debt	9,615	13,407	13,505
Net debt excl. Parent company loans and pension liabilities	9,133	13,018	13,103
Leverage ¹⁾	5.5x	5.7x	5.6x

¹⁾ Net debt excluding pension liabilities and shareholder loans/EBITDA excluding non-recurring items.

Free cash flow July – September

Free Cash flow improved during the third quarter 2019 driven by improved earnings and release of working capital and amounted to SEK 301 m (174). Utilization of the factoring program at September 30, 2019 amounted to EUR 82 (115) m.

Free cash flow January - September

Free Cash flow for the first 9 month amounted to SEK 532 (518) m. The free cash flow was negatively impacted by lower earnings in combination with somewhat higher investments, counterbalanced by favorable development of working capital.

Net debt and leverage

The Group's available funds, liquid funds and unutilized credit facilities, amounted to SEK 942 (1,119) m at the end of the period, compared with SEK 1,120 m at the end of 2018.

Following the company's positive development during 2018 and the sale of the Bioproduct and Caprolactone businesses, Perstorp, refinanced the capital structure with new credit facilities in the first quarter 2019.

Leverage was 5.5x at the end of the third quarter 2019 compared to 5.6x at the end of 2018.

Business Area Speciality Polyols & Solutions

Business Area

Specialty Polyols & Solutions

SEK m	Quar	ter 3	Quarter 1-3		
	2019	2018	2019	2018	
Continuing operations					
Net sales	1,564	1,732	5,085	5,405	
EBITDA	296	239	824	899	
EBITDA excl. non-recurring items	296	239	825	901	
EBITDA margin excl. non-recurring items, %	18.9	13.8	16.2	16.7	

Specialty Polyols & Solutions consists of Business units Penta, TMP/Neo, Formates and Business Development.

July - September 2019

Net sales in the third quarter 2019 amounted to SEK 1,564 (1,732) m. The lower sales were mainly attributable to weaker demand and increased price pressure in EMEA and APAC mainly for the TMP and Neo product lines. Exchange rates had a positive impact on sales of approximately 4%.

Organic volume based sales growth was -1%.

EBITDA excluding non-recurring items in the third quarter was SEK 296 (239) m corresponding to an EBITDA margin of 18.9% (13.8%). The increase was mainly driven by improved margins for most product lines, lower fixed costs and positive exchange rate effects. To some extent this was offset by lower volumes on TMP and Neo as well as lower margins on Neo.

Business Area Advanced Chemicals

Business Area

Advanced Chemicals

SEK m	Quar	ter 3	Quarter 1-3		
	2019	2018	2019	2018	
Continuing operations					
Net sales	937	961	3,011	3,086	
EBITDA	140	95	454	379	
EBITDA excl. non-recurring items	138	98	454	382	
EBITDA margin excl. non-recurring items, %	14.7	10.2	15.1	12.4	

Business Area Advanced Chemicals consists of Business units Oxo and Plasticizers.

July-September 2019

Net sales in the third quarter 2019 amounted to SEK 937 (961) m. Negative impact from increased price pressure and softer demand for some product lines was partly offset by higher volumes and positive exchange rate effect. Exchange rates had a positive impact on sales of approximately 3%.

Organic volume base sales growth was +4%.

EBITDA excluding non-recurring items, in the third quarter, amounted to SEK 138 (98) m, corresponding to an EBITDA margin of 14.7% (10.2). The increase was mainly due to improved unit margins on both the alcohol and plasticizer product lines, somewhat higher volumes for alcohols and positive exchange rate effects.

Business Area Animal Nutrition

Business Area

Animal Nutrition

SEK m	Quar	ter 3	Quarter 1-3		
	2019	2018	2019	2018	
Continuing operations					
Net sales	313	310	925	947	
EBITDA	49	58	163	193	
EBITDA excl. non-recurring items	49	58	163	194	
EBITDA margin excl. non-recurring items, %	15.7	18.7	17.6	20.5	

Business Area Animal Nutrition consists of Business Units Feed Additives and Acids and Salts.

July - September 2019

Net sales in third quarter 2019 amounted to SEK 313 (310) m. Volume growth was positive for most product lines compared to same period last year. The decrease in sales was attributable to a combination of increased price pressure and availability for some product lines offset by favorable supple-demand balance for some products together with a positive exchange rate impact. Exchange rates had an impact on sales of approximately 3%.

Organic volume based sales growth was +6%

EBITDA excluding non-recurring items in the third quarter was SEK 49 (58) m corresponding to an EBITDA margin of 15.7% (18.7%). The decrease was a result of lower unit margins linked to increased price competition together with negative product and customer mix for some product lines.

Consolidated income statement

Income statement, consolidated group

SEK m Note	Quai	rter 3	Quart	er 1-3	Latest	Full year
Continuing operations	2019	2018	2019	2018	12 months	2018
Net Sales 3	2,895	3,037	9,178	9,498	12,116	12,436
Cost of goods sold	-2,427	-2,599	-7,707	-7,941	-10,170	-10,404
Gross earnings	468	438	1,471	1,557	1,946	2,032
Selling, administration and R&D costs	-182	-201	-629	-624	-843	-838
Other operating income and expenses ¹⁾	-6	22	-47	98	-100	45
Write-down of assets	-11	-3	-11	-57	-11	-57
Result from participations in associated companies	1	1	4	4	3	3
Operating earnings (EBIT) 5	270	257	788	978	995	1,185
Exchange-rate effects on net debt	-140	107	-376	-445	-393	-462
Other financial income and expenses	-163	-336	-1,502	-987	-1,923	-1,408
Earnings/loss before tax	-33	28	-1,090	-454	-1,321	-685
Tax 7	-27	-21	-82	271	377	730
Net earnings/loss	-60	7	-1,172	-183	-944	45
Discontinued operation 8						
Net sales 3	-	692	113	1,860	699	2,446
Operating earnings (EBIT)	-	121	4,760	276	4,869	385
Earnings/loss before tax	0	81	4,758	153	4,810	205
Tax	0	-11	-12	-27	-11	-26
Net earnings/loss	0	70	4,746	126	4,799	179
Group, total						
Net sales	2,895	3,729	9,290	11,358	12,814	14,882
Operating earnings (EBIT)	270	377	5,548	1,253	5,865	1,570
Earnings/loss before tax	-33	110	3,668	-300	3,488	-480
Tax	-26	-33	-94	243	367	704
Net earnings/loss	-59	77	3,574	-57	3,855	224

Consolidated Group

EBITDA	3, 5, 8	411	524	5,955	1,743	6,403	2,191
EBITDA excluding non-recurring items	3, 5, 8	440	566	1,359	1,796	1,887	2,324

¹⁾ Other operating income and expenses primarily includes currency translation effects on operational net receivables and non-recurring income and costs.

Consolidated income statement

Comprehensive income report

SEK m	Quar	ter 3	Quarter 1-3		Latest	Full year
	2019	2018	2019	2018	12 months	2018
Net result for the period	-59	77	3,574	-57	3,855	224
Other comprehensive income						
Items that will not be reclassified to profit or loss						
Remeasurements of defined benefit plan	-55	1	-55	1	-61	-5
Items that may be subsequently reclassified to profit or loss						
Currency translation effect	-66	-42	-31	-33	-47	-49
Other comprehensive income net after tax	-121	-41	-86	-32	-108	-54
Total comprehensive income	-180	36	3,488	-89	3,747	170
Attributable to:						
Parent company's shareholder	-188	31	3,459	-127	3,710	124
Non-controlling interest	8	5	29	38	37	46

Consolidated balance sheet

Balance sheet, consolidated group

SEK m Note	Sept 30, 2019	Sept 30, 2018	Dec 31, 2018
Tangible fixed assets	4,690	5,076	4,502
Intangible fixed assets	4,437	4,840	4,381
Participation in associated companies	75	72	72
Other non-current assets 7	1,172	875	1,217
Inventories	1,525	1,586	1,620
Other current assets	1,425	1,436	1,206
Cash & cash equivalents, incl. short-term investments	271	385	565
Assets held for sale	-	-	1,320
Total assets	13,595	14,270	14,883
Total equity 6	1,230	-2,480	-2,250
Pension liability, others	493	388	403
Other non-current liabilities	10,072	14,111	14,346
Current liabilities	1,800	2,251	2,197
Liabilities held for sale	-	-	187
Total equity & liabilities	13,595	14,270	14,883
Working capital 4	1,178	1,249	789
Net debt 9	9,615	13,407	13,505
Net debt excluding parent company loan	0 122	12,010	12 102
and pension labilities	9,133	13,018	13,103
Capital employed	11,093	11,203	11,718
Number of full-time employees, end of period	1,367	1,577	1,501
Contingent liabilities	282	238	239
Assets pledged	6,358	7,209	3,965

Consolidated statement of changes in equity

Total equity, 2019

SEK m	Note	Equity attributable to owners of the parent	Non-controlling interest	Total equity
Opening balance, January 1, 2019		-2,378	128	-2,250
Change in accounting principles	5	-7	-	-7
Adjusted opening balance, January 1, 2019		-2,385	128	-2,257
Total comprehensive income		3,459	29	3,488
Transactions with owners, recognized				
directly in equity		-	-1	-1
Closing balance, September 30, 2019		1,074	156	1,230

Total equity, 2018

SEK m	Equity attributable to owners of the parent	Non-controlling interest	Total equity
Opening balance, January 1, 2018	-2,527	144	-2,383
Total comprehensive income	-127	38	-89
Dividend to non-controlling interest	-	-35	-35
Transactions with owners, recognized			
directly in equity	25	2	27
Closing balance, September 30, 2018	-2,629	149	-2,480

Consolidated cash flow statement

SEK m	Qua	rter3	Quart	ter 1-3	Latest	Full year
	2019	2018	2019	2018	12 months	2018
Operating activities						
Operating earnings	270	257	788	978	995	1,185
Adjustments						
Depreciation and write-down	141	118	398	407	502	511
Other	11	-27	-131	-41	-145	-55
Operating activities in discontinued operations	-	148	78	358	229	509
Interest received and other financial items	2	0	4	4	7	7
Interest paid and other financial items	-205	-12	-1,249	-526	-1,814	-1,091
Income tax paid	-6	-18	-46	-82	-54	-90
Interest and taxes paid in discontinued operation	-	-48	-6	-116	-42	-152
Cash flow from operating activities before change in operating capital	213	418	-164	982	-322	824
Changes in working capital Increase (-) Decrease (+) in net working capital ¹⁾	30	-114	-366	-587	-90	-311
Discontinued operations	-	-64	-38	-72	131	97
Cash flow from operating activities	243	240	-568	323	-281	610
Investing activities						
Acquisition of net assets, subsidiaries	-	-	-	-5	-23	-28
Investments in other participations	-	-	-2	-	-5	-3
Acquisition of tangible and intangible fixed assets	-168	-129	-381	-329	-564	-512
Sale of net assets, subsidiaries	-	-	6,057	-	6,085	28
Sale of shares, other participations	-	-	5	-	5	-
Sale of tangible and intangible fixed assets	-	-	-	1	0	1
Discontinued operations	-	-38	-7	-86	-41	-120
Cash flow from investing activities	-168	-167	5,672	-419	5,457	-634
Financing activities						
Dividend paid to non-controlling interests in subsidiaries	-	-	-29	-35	-29	-35
New loans	-	-	8,800	-	8,800	-
Amortization of loans	-10	-	-13,978	-	-13,978	-
Change in credit utilization ³⁾	-133	-307	-209	-107	-109	-7
Cash flow from financing activities	-143	-307	-5,416	-142	-5,316	-42
Change in liquid funds	-68	-234	-312	-238	-140	-66
Liquid fund opening balance, incl. short-term investments	333	632	565	621	385	621
Translation difference in liquid funds	6	-13	18	2	26	10
Liquid funds, end of period ²⁾	271	385	271	385	271	565
 ¹⁾ Including trade receivable financing program ²⁾ Restricted and held on escrow ³⁾ Including payment of bank fees related to refinancing 	185	137	185	137	185	208

Parent company

Perstorp Holding AB (publ.) is fully owned by Financière Forêt S.á.r.l and the parent company of the Perstorp Holding Group. Perstorp Holding AB (publ.) had no external sales. Shareholder's equity at September 30, 2019 amounted to 3,410 m (1,205) compared to SEK 4,919 m at December 31, 2018.

Income statement

SEK m	Note	Quar	ter 3	Quart	ter 1-3	Latest	Full year
		2019	2018	2019	2018	12 months	2018
Net Sales		31	29	52	61	62	71
Gross earnings		30	29	51	61	61	71
Sales, marketing and admin costs		-56	-53	-140	-141	-171	-172
Other operating income and expenses		-6	-1	-11	-7	-32	-28
Operating earnings (EBIT)		-32	-25	-100	-87	-142	-129
Financial income and expenses $^{\mbox{\tiny 1}\mbox{\tiny }}$		-136	-86	-1,409	132	-1,679	-138
Appropriations		-	-	-	-	4,260	4,260
Earnings/loss before tax		-168	-111	-1,509	45	2,439	3,993
Tax	7	-	-	-	317	-233	84
Net earnings/loss ²⁾		-168	-111	1,509	362	2,206	4,077
¹⁾ Including dividends from subsidiaries		-	-	-	1,100	-	1,100

²⁾ Comprehensive income equals net earnings/loss for the year

Balance sheet

SEK m	Note	Sept 30, 2019	Sept 30, 2018	Dec 31, 2018
Tangible fixed assets		0	1	1
Intangible fixed assets		1	1	1
Shares in group companies		7,731	7,731	7,731
Long term receivables group		5,657	7,117	9,878
Other non-current assets	7	426	683	394
Short term financial receivables group		78	436	1,649
Other current assets		31	20	24
Cash & cash equivalents		0	0	23
Total assets		13,924	15,989	19,701
Total equity	6	3,410	1,205	4,919
Other non-current liabilities		9,263	13,192	13,364
Current liabilities		1,251	1,592	1,418
Total equity & liabilities		13,924	15,989	19,701





Key figures and FX rates

Key figures

SEK m unless otherwise stated		201	9	2	018
	Q3	Q2	Q1	Q4	Q3
Continuing operations					
Net Sales	2,895	3,065	3,218	2,938	3,037
Organic volume-based sales growth, %	1.7	-5.6	0.0	-6.7	-7.5
Marginal contribution	829	874	943	811	828
EBITDA excluding non-recurring items	439	365	475	376	417
% of net sales	15.2	11.9	14.8	12.8	13.7
Cash conversion, % of EBITDA excluding non-recurring items	69	61	2	118	42
Consolidated Group					
Net earnings/loss	-59	-52	3,685	281	77
Earnings, per share, diluted, SEK	-1,20	-1,04	73.71	5.63	1.53
Net debt excluding pension liabilities and shareholder loans	9,133	8,883	8,822	13,103	13,018
Leverage ¹⁾	5.5x	5.4x	5.0x	5.6x	5.7x

¹⁾ Net debt excluding pension liabilities and shareholder loans/EBITDA excluding non-recurring items.

Currency rates

Closing rate					
USD	9.80	9.27	9.28	8.97	8.86
EUR	10.73	10.56	10.42	10.28	10.29
GBP	12.07	11.75	12.08	11.35	11.57
Average rate					
USD	9.59	9.45	9.17	9.04	8.95
EUR	10.66	10.62	10.42	10.32	10.41
GBP	11.81	12.15	11.94	11.65	11.66

Notes

1. Accounting & valuation principles

The consolidated financial statements for Perstorp Holding AB have been prepared in accordance with IAS 34, Interim Financial Reporting, and the applicable regulations of the Swedish Annual Accounts Act. The Interim Report for the parent company has been prepared in accordance with the Swedish Annual Accounts Act's chapter 9, Interim Reporting. The same accounting principles and calculation methods used in the interim reports were used in the annual accounts for 2018. The accounting principles of the Group and parent company are stated in Note 2 of the 2018 Annual Report.

Segment information

During the first quarter Perstorp announced a new organization with three new Business Areas (BAs) to manage our different customer categories and maintain strong customer intimacy:

- BA Specialty Polyols & Solutions: BU Penta, BU TMP & NEO and BU Formates
- BA Advanced Chemicals: BU Oxo and BU Plasticizers
- BA Animal Nutrition: Feed Additives and Acids and Salts

The historical numbers have been restated according to the new organization.

As a consequence, 56 employees were made redundant globally and a restructuring provision amounting to approximately SEK 45 million is reported as a non-recurring item in the income statement for continuing operations.

IFRS 16 - Leasing

IFRS 16 Leases was implemented from 1 January 2019. This Standard regulates the recognition of leases and replaces IAS 17 "Leases" and the associated IFRIC 4, SIC-15 and SIC-27 interpretation statements. The Standard requires that assets and liabilities related to all lease arrangements are recognized in the Balance Sheet with certain exceptions. Recognition is based on the view that the lessee is entitled to use an asset for a specific period of time and has a simultaneous obligation to pay for that right.

Work on analyzing and evaluating the effects of adoption of the new Standard on the Group's financial reporting has been performed and the Group has identified over 200 arrangements at the year-end 2018. Contracts governing rights of use with a shorter term than 12 months or with acquisition costs of less than USD 5,000 are not included. A marginal lending rate has been set by region.

Perstorp Group separate the non-lease components from the lease components related to rental of premises, leased cars and IT equipment. For rental of storage tanks these payments include non-lease components as they are not possible to separate from lease payments. The incremental borrowing rates used for discounting lease payments are based on the same principals as borrowings within the Group, cost of funds for long-term or short-term borrowing, plus an additional credit spread to reflect the slightly weaker creditworthiness of the borrower compared to the consolidated Perstorp Group.

Perstorp Group applies IFRS 16 retrospectively with the cumulative effect of initially applying the standard recognized at the 1st of January 2019, the so called modified retrospective approach. This means that no comparative figures will be recalculated and the full effect of the Standard are restated in the opening balances for 2019.

For essentially all of its leases, Perstorp Group has decided to measure the opening balance of the right-of-use assets as if IFRS16 has been applied since the commencement date, but discounted using the incremental borrowing rate at the 1st January 2019. For portfolios including leases with reasonably similar characteristics, the same discount rate has been used for all leases included in a portfolio. A right-of-use asset and a lease liability need not be measured for leases for which

the lease term ends within 12 months of the date of initial application. Therefore, no assets or liabilities have been measured for leases with an end date during 2019. Initial direct costs have been excluded from the measurement of the right-of-use assets at the date of initial application.

Hindsight has been used, such as in determining the lease term if the contract contains options to extend or terminate the lease. This practical expedient means that Perstorp Group been able to solely use information that existed at around the implementation when it comes to determining the lease term. For further information see note 5.

2. Definitions non IFRS measures

"Marginal contribution" is calculated as the difference between net sales and the variable elements of the Group's cost of goods sold, being variable production and distribution cost, freight and commission costs.

"EBITDA" represents the Group's operating earnings (or loss) (EBIT) before depreciation and amortization.

"EBITDA margin (adjusted for non-recurring items)" is calculated as EBITDA (adjusted for non-recurring items) divided by net sales.

"EBIT" is calculated as the Group's reported operating earnings (loss).

"Free cash flow" is calculated as EBITDA (excluding non-recurring items) less change in working capital excluding exchange rate effects and provisions and investments.

"Cash conversion" is calculated as free cash flow divided by EBITDA (adjusted for non-recurring items). "Organic volumebased sales growth" is defined as change in organic production volume sold (i.e., sold production volume times product price) between successive periods assuming a constant price over the relevant period and excluding foreign exchange effects and the impact of acquisitions.

"Continuing operations" excludes the divested units Perstorp UK Ltd, Perstorp Bioproducts AB and Perstorp Bioproducts AS.

3 Segment information ¹⁾

SEK m	Qua	rter 3	Quart	er 1-3	Latest	Full year
	2019	2018	2019	2018	12 months	2018
Net Sales						
Specialty Polyols & Solutions	1,564	1,732	5,085	5,405	6,688	7,008
Advanced Chemicals	937	961	3,011	3,086	3,997	4,072
Animal Nutrition	313	310	925	947	1,214	1,236
Internal sales						
Specialty Polyols & Solutions	0	-19	-2	-72	-18	-88
Advanced Chemicals	-132	-163	-413	-508	-523	-618
Animal Nutrition	-2	-4	-10	-10	-19	-19
Other/eliminations	215	220	582	650	777	845
Continuing operations	2,895	3,037	9,178	9,498	12,116	12,436
Discontinued operations	0	692	112	1,860	698	2,446
TOTAL GROUP	2,894	3,729	9,290	11,358	12,814	14,882
EBITDA			1			
Specialty Polyols & Solutions	296	239	824	899	1,076	1 151
Advanced Chemicals	140	95	454	379	556	481
Animal Nutrition	49	58	163	193	210	240
Other/eliminations	-74	-17	-255	-86	-345	-176
Continuing operations	411	375	1,186	1,385	1,497	1,696
Discontinued operations	0	149	4,769	358	4,906	495
TOTAL GROUP	411	524	5,955	1,743	6,403	2,191
Non allocated items						
Depreciation, Amortization and write down	-141	-147	-407	-490	-538	-621
Operating earnings (EBIT)	270	377	5,548	1,253	5,865	1,570
Financial income and expenses	-303	-267	-1,880	-1,553	-2,377	-2,050
Earnings/loss before tax	-33	110	3,668	-300	3,488	-480
Tax	-26	-33	-94	243	367	704
Net result	-59	77	3,574	-57	3,855	224
EBITDA excluding non-recurring items						
Specialty Polyols & Solutions	296	239	825	901	1,089	1,165
Advanced Chemicals	138	98	454	382	556	484
Animal Nutrition	49	58	163	194	210	241
Other/eliminations	-44	22	-163	-39	-200	-76
Continuing operations	439	417	1,279	1,438	1,655	1,814
Discontinued operations	0	149	80	358	232	510
TOTAL GROUP	440	566	1,359	1,796	1,887	2,324

¹⁾ The Group is domiciled in Sweden. The result of its net sales from external customers in Sweden is 6% (4), and the total of net sales from external customers from other countries is 94% (96). No sales above 10% derived from a single external customer.

4. Working Capital

SEK m	Sept 30, 2019	Sept 30, 2018	Dec 31, 2018
Inventories	1,525	1,450	1,661
Accounts receivable	948	880	863
Other current assets	370	305	344
Accounts payable	-596	-661	-967
Other current liabilities	-1,069	-876	-1,129
Total working capital – continuing operations	1,178	1,098	772
Discontinued operations	-	151	17
Total Group	1,178	1,249	789

5. Leasing

SEK m	Jan 1, 2019
Impact on opening balance	
Right of use assets	100
Lease liabilities	109
Deferred tax assets	2
Equity	-7

SEK m	Quarter 3, 2019	Quarter 1-3, 2019
Impact on income statement, IFRS16 ¹⁾		
Depreciation on right of use assets	-9	-28
Interest on lease liability	-2	-6

¹⁾ The effect on EBITDA of the transition is approximately SEK 11 m in the third quarter and SEK 34 m for the first 9 months.

6. Equity

At the end of September 2019 equity for the parent company, Perstorp Holding AB, amounts to SEK 3,410 (1,205) m. Consolidated equity, including non-controlling interest, for the Perstorp Group amounts to SEK 1,230 (-2,480) m.

7. Effects of changed tax rules in Sweden

The proposal for new tax rules in Sweden was adopted on the 14th of June 2018. The new rules applies from the 1st of January 2019. The areas that affects the accounting and reporting in this report are the change in the corporate tax rate and the general interest rate deduction rules. A change in the tax rate affects the valuation of deferred tax assets and deferred tax liabilities, while the interest-rate limitation rules can have an effect on the companies' ability to report deferred tax assets related to tax losses carry forward.

8. Divestment

On December 10th, 2018 Perstorp announced the agreement to sell its Caprolactone business. The transaction was closed on February 13th 2019, the net proceeds from the transaction was approximately EUR 579 m. The capital gain amounts to approximately SEK 4,6 billion. At year end 2018 the assets and liabilities are classified as assets and liabilities held for sale in the balance sheet. In the income statement this is classified as discontinued operations.

In November 2018, Perstorp announced and completed the divestment of its Bioproduct business in order to streamline the portfolio. The Bioproduct business was concentrated to Sweden and Norway. In the income statement this is classified as discontinued operations.

9. Financing

During the first quarter 2019, Perstorp issued redemption notices for all outstanding bonds and notes issued by Prague CE S.A.R.L.. The redemption was financed by the proceeds of the Caprolactone sale as well as new credit facilities, with lower interests, committed by Bank of America, Merrill Lynch, Goldman Sachs Bank USA, DNB, SEB, Standard Charted Bank and Nordea.

10. Risk and uncertainty

Perstorp is exposed to a number of risks and uncertainty factors, which are reviewed in the Annual Report for 2018.

11. Other information

No major events have occurred since the balance sheet date and up to the publication of this report. Perstorp's financial information comprises of Interim-, Annual- and a Sustainability report.

The complete Annual Report for the full year 2018, is available in English and can be ordered in print format and can also be downloaded from the Group's website at <u>www.perstorp.com</u>.

Perstorp, October 23, 2019

Jan Secher, President and CEO

The report has not been reviewed by Perstorp's auditors.

One molecule can change everything

Perstorp believes in improving everyday life – making it safer, more convenient and more environmentally sound for billions of people all over the world. As a world leading specialty chemicals company, our innovations provide essential properties for products used every day and everywhere. You'll find us everywhere from your car and smart phone to towering skyscrapers and the local dairy farm. Simply put, we work to make good products even better, with a clear sustainability agenda.

Founded in Sweden in 1881, Perstorp's focused innovation builds on more than 135 years of experience, representing a complete chain of solutions in organic chemistry, process technology and application development. Perstorp has approximately 1,350 employees and manufacturing units in Asia, Europe and North America. Sales in 2018 amounted to 12.4 billion for continuing operations.

Learn more at <u>www.perstorp.com</u>